English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In this study, the feasibility of using the novel anisamide-lipid calcium phosphate nanoparticles (AS-LCPs) as a nanocarrier for the delivery of biologically active oridonin (ORD) was evaluated on lung cancer models. In addition to the characterization, release behaviors, and stability of AS-ORD LCPs, we also studied their pharmacokinetics and targeting ability by  in vivo  imaging. Finally, we investigated the effect of ORD on the anti-tumor efficiency of the AS-LCPs based on weight, tumor inhibition, and the survival time of mice. The average particle size of the AS-ORD LCPs was 129.5 ± 23.7 nm, the polydispersity index (PDI) was 0.16 ± 0.03, and the zeta potential was 23.6 ± 3.4 mV. The AS-ORD LCPs were proved to be stable under both long-term and accelerated storage conditions. The AS-ORD LCPs showed sustained release  in vivo  and faster release in acidic environment, which was favorable to drug release in tumor environment.  In vivo  studies showed that depending on surface modification, AS-ORD LCPs which suggested that cell internalization was change and more drugs entered the cells successfully. Therefore, AS-ORD LCPs could be a promising formulation for the treatment of lung cancer.

Oridonin-loaded lipid-coated calcium phosphate nanoparticles: preparation, characterization, and application in A549 lung cancer